Docoh
Loading...

IMUX Immunic

News

From Benzinga Pro
Immunic, Inc. Announces Enrollment Of First Patient In Its Phase 3 ENSURE Program Of Vidofludimus Calcium In Relapsing Multiple Sclerosis
18 Nov 21
Biotech, News, FDA, General
Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today
Immunic Q3 EPS $(0.76) Beats $(0.78) Estimate
4 Nov 21
Earnings, News
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.78) by 2.56 percent. This is a 8.57 percent decrease over losses of $(0.70) per share from the same
Earnings Scheduled For November 4, 2021
4 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.
Immunic, Inc. Announces Completion Of Enrollment Of Its Phase 2 CALDOSE-1 Trial Of IMU-838 In Moderate-to-Severe Ulcerative Colitis
28 Oct 21
Biotech, News, FDA, General
Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that the
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
7 Oct 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6)
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
6 Oct 21
Biotech, News, Penny Stocks, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5)
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
5 Oct 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4)
Immunic, Inc. Enrolls First Patient In Its Phase 2 CALLIPER Trial Of IMU-838 In Progressive Multiple Sclerosis
30 Sep 21
Biotech, News, FDA, General
Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced
Immunic, University Medical Center Goettingen Ink Licensing Pact For Combination Viral Infection Treatments
22 Sep 21
Biotech, News, Health Care, Contracts, Movers, Trading Ideas, General
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
22 Sep 21
Pre-Market Outlook, Markets, Movers
Immunic And The University Medical Center Goettingen Sign License Agreement Covering The Combination Of DHODH Inhibitors And Nucleoside Analogues To Treat Viral Infections, Including COVID-19
22 Sep 21
News, Contracts
Immunic, Inc. (NASDAQ:IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced
10 Biggest Price Target Changes For Tuesday
7 Sep 21
Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
Morgan Stanley raised NIKE, Inc. (NYSE: NKE) price target from $214 to $221. NIKE shares fell 0.1% to $163.21 in pre-market trading.
HC Wainwright & Co. Maintains Buy on Immunic, Lowers Price Target to $25
7 Sep 21
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $40 to $25.

Press releases

From Benzinga Pro
Immunic, Inc. to Participate in the Piper Sandler & Co. 33rd Annual Virtual Healthcare Conference
23 Nov 21
Press Releases
NEW YORK, Nov. 23, 2021 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and
Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis
18 Nov 21
Press Releases
NEW YORK, Nov. 18, 2021 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and
Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activity
4 Nov 21
Earnings, Press Releases
NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2021 and Provide Corporate Update
1 Nov 21
Press Releases
NEW YORK, Nov. 1, 2021 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and
Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis
28 Oct 21
Press Releases
NEW YORK, Oct. 28, 2021 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune
Immunic, Inc. Announces First Psoriasis Patient Enrolled in Ongoing Phase 1 Trial of IMU-935
27 Oct 21
Press Releases
NEW YORK, Oct. 27, 2021 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and
Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer
14 Oct 21
Press Releases
NEW YORK, Oct. 14, 2021 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and
Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis
30 Sep 21
Press Releases
NEW YORK, Sept. 30, 2021 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and
Immunic, Inc. to Participate in Scientific and Investor Conferences in October
28 Sep 21
Press Releases
NEW YORK, Sept. 28, 2021 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and
Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19
22 Sep 21
Press Releases
NEW YORK and GOETTINGEN, Germany, Sept. 22, 2021 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating
Immunic, Inc. to Participate in Investor and Scientific Conferences in September
8 Sep 21
Press Releases
NEW YORK, Sept. 8, 2021 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and